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Background: Pancreatic cancer, one of the most dreadful gastrointestinal tract malignancies, with the current
chemotherapeutic drugs has posed a major impediment owing to poor prognosis and chemo-resistance thereby
suggesting critical need for additional drugs as therapeutics in combating the situation. Fluoroquinolones have
shown promising and significant anti-tumor effects on several carcinoma cell lines.
Methods: Previously, we reported growth inhibitory effects of fourth generation fluoroquinolone Gatifloxacin, while
in the current study we have investigated the anti-proliferative and apoptosis-inducing mechanism of older
generation fluoroquinolones Moxifloxacin and Ciprofloxacin on the pancreatic cancer cell-lines MIA PaCa-2 and
Panc-1. Cytotoxicity was measured by MTT assay. Apoptosis induction was evaluated using annexin assay, cell cycle
assay and activation of caspase-3, 8, 9 were measured by western blotting and enzyme activity assay.
Results: Herein, we found that both the fluoroquinolones suppressed the proliferation of pancreatic cancer cells by
causing S-phase arrest and apoptosis. Blockade in S-phase of cell cycle was associated with decrease in the levels of
p27, p21, CDK2, cyclin-A and cyclin-E. Herein we also observed triggering of extrinsic as well as intrinsic mitochondrial
apoptotic pathway as suggested by the activation of caspase-8, 9, 3, and Bid respectively. All this was accompanied by
downregulation of antiapoptotic protein Bcl-xL and upregulation of proapoptotic protein Bak. Our results strongly
suggest the role of extracellular-signal-regulated kinases (ERK1/2), but not p53, p38 and c-JUN N-terminal kinase (JNK)
in fluoroquinolone induced growth inhibitory effects in both the cell lines. Additionally, we also found both the
fluoroquinolones to augment the apoptotic effects of broad spectrum anticancer drug Cisplatin via ERK.
Conclusion: The fact that these fluoroquinolones synergize the effect of cisplatin opens new insight into therapeutic
index in treatment of pancreatic cancer.
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Pancreatic cancer is one of the most dreadful gastro-
intestinal tract malignancies, owing to its poor diagnosis,
rare curative surgeries and less understood etiology [1].
The survival rate period of 5-years is less than 5 %, which
is an issue of apprehension. Till date the only curative op-
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article, unless otherwise stated.under 20 % and the median survival rate is rarely more
than 20 months. Impact of the post-operative complica-
tions on long-term survival after resection of pancreatic
cancer is not well reported. According to several studies,
the postoperative mortality rates are less than 6 % in spe-
cialized centres with an overall morbidity rate of 20-50 %
[2, 3]. Unresectable cases generally receive chemothera-
peutic treatment comprising of a standard Gemcitabine
(2′, 2′-difluorocytidine) alone or in combination with
Erlotinib or Folfirinox [4]. Recently Goldstein et al., showed
superior efficacy of combined therapy of Nab-paclitaxele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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However to our dismay, almost all patients suffering from
advanced stage pancreatic carcinoma develop an inherent
resistance to Gemcitabine, the mechanisms of which is yet
unknown [6]. As each of the therapies has limitations,
hence there is always a need for new strategies to improve
the treatment efficacy of this fatal disease.
Fluoroquinolones (FQ) are broad spectrum antibiotics
and are active against various gram positive and gram
negative bacteria, specifically by targeting bacterial DNA
gyrase and topoisomerase [7, 8]. Apart, from their antibac-
terial, antimycobacterial and other clinical implications,
traditional FQ family members MFX and CFX are also
known to have several immunomodulatory effects in vitro
in various cell lines [9–11]. Previous reports focusing on
the ability of FQs to induce apoptosis and cell cycle arrest
in various cancer cell lines alone or in combination with
other chemotherapeutic agents have rendered them unique
among other antibiotic family members [12–18].
Previously we reported that the newer generation FQ,
Gatifloxacin possesses antiproliferative activity against
pancreatic cancer cell lines by causing S/G2 phase cell
cycle arrest without induction of apoptosis through p21,
p27 and p53 dependent pathway [20]. Herein, we have
investigated the effect of MFX and CFX on survival and
proliferation of pancreatic cancer cell lines (MIA PaCa-2
and Panc-1) and found that both were able to suppress
the proliferation of pancreatic cancer cells and induce
apoptosis through similar mechanism. In addition our
results also suggest that both the FQ augments the
apoptotic effects of Cisplatin (CDDP) via ERK activation.
Methods
Reagents and antibodies
DMEM, Antibiotic Antimycotic solution, Trypsin EDTA,
Dimethyl sulfoxide (DMSO), propidium iodide (PI), pro-
tease and phosphatase inhibitor cocktail, BCIP-NBT,
BCA reagent, carbonyl cyanide m-chlorophenyl hydra-
zone (mClCCP; a mitochondrial uncoupler), 3,3′-dihexy-
loxacarbocyanine iodide (DiOC6), MTT, ERK inhibitor
(U0126), p38 inhibitor (SB203580), Cisplatin (CDDP) were
purchased from Sigma (St. Louis, Missouri, USA). Caspase-
8 inhibitor and zVAD-fmk (carbobenzoxy-valyl-alanyl-aspar-
tyl-[O-methyl]-fluoromethyl-ketone) were from calbiochem,
Germany. Foetal bovine serum was purchased from Bio-
logical Industries (Kibbutz Beit Haemek, Israel). Anti-
bodies Cyclin-A, Cyclin-E, CDK-2, Cyclin-B1, p21, p27,
Bid, PARP, cleaved caspase-3, −8, −9 were purchased from
Cell signaling technologies (MA, USA). Antibodies Bax,
Bak, Bcl-xL, cMyc, GAPDH, pAKT (Ser 473), AKT, p53,
pCDC2, CDC2, CDC25c, pP38, total P38, pJNK, total
JNK, pERK1/2, total ERK were purchased from Santacruz
biotechnology (Santa Cruz, CA, USA). MFX and CFX
were obtained from Cipla (India).Cell culture
MIA PaCa-2 and Panc-1 cells were obtained from
National Centre for Cell Science, Pune, India and main-
tained in DMEM medium containing 10 % (v/v) FBS, 100
units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml
amphotericin-B in a humidified 5 % CO2 atmosphere.
Both the cell lines harbour mutations in their p53 gene. In
MIA PaCa-2 cells, Arginine is substituted with Tryptophan
at 248-position and in Panc-1 cells, Arginine is substituted
with Cysteine at 273-position [19]. Cells growing in loga-
rithmic phase were used in all experiments. Synchronized
and growth arrested cultures were then subjected to MFX
and CFX (0–400 μg/ml) treatment in complete media for
24 h and 48 h respectively. Wherever indicated, flow cy-
tometry and western blot analysis (described below) were
done using U0126 (5 μM for MIA PaCa-2 and 10 μM for
Panc-1) in DMSO. For control, equivalent volume of
DMSO was added to the culture medium 1 h prior to the
treatment.
Cell viability assay
Cell viability assay was performed using MTT [3-(4, 5-
dimethyl thiazol-2yl)-2, 5-diphenyltetrazolium bromide].
10,000 cells per well were seeded in 96 well plates and
treated with different concentrations (0–400 μg/ml) of
MFX and CFX in triplicates. As controls, Dextrose 5 %
(w/v) treated cells (Vehicle) were included in each exper-
iments. Post treatment, 10 μL of MTT (5 μg/ml) was
added to each well and incubated for 3 h at 37 °C in
dark. Formazan crystals formed were dissolved in 100 μl
DMSO and the absorbance was measured at 570 nM
using an ELISA reader. Cell viability was calculated as
reported earlier [21].
Annexin assay
Apoptosis was assessed using Guava Nexin kit and Guava
PCA system according to the manufacturer’s protocol
(Guava Technologies, Hayward, California, USA). The
assay uses AnnexinV-PE to detect the translocation of
phosphatidylserine onto the surface of apoptotic cells. 7-
amino actinomycin-D (7-AAD), the cell impermeable dye
is included in the Guava Nexin Reagent, which is excluded
from live healthy cells and early apoptotic cells but perme-
ates late-stage apoptotic and dead cells.). AnnexinV-PE
fluorescence was analyzed by cytosoft software (Guava
Technologies, Hayward. California, USA). A minimum of
2000 events were counted.
Cell cycle analysis
For analysis of cell cycle distribution, 1 × 106 cells were
harvested by centrifugation, washed with phosphate-
buffer saline (PBS), fixed with ice cold 70 % ethanol and
treated with 1 mg/ml RNAse for 30 min. Intracellular
DNA was labelled with propidium iodide (50 μg/ml) and
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using flow cytometer (Guava Technologies, Hayward,
California, USA) and cytosoft software (Guava Technolo-
gies, Hayward, California, USA). A minimum of 5,000
events were counted [20].
DNA fragmentation and caspase activity assay
For DNA fragmentation analysis, 48 h post CFX/MFX
treatment DNA was isolated according to manufacturer’s
protocol (BioVision Incorporated, Milpitas, California,
USA). In brief, FQ treated cells were harvested and re-
suspended in 50 μl of ice cold lysis buffer containing
10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA
and 0.5 % Triton X-100 by gentle pipetting. Isolated
DNA was precipitated and analyzed electrophoretically
on 1.8 % agarose gel containing ethidium bromide using
UV-spectrophotometer.
Caspase-3, −8 and −9 activities were determined using the
respective colorimetric substrates (Calbiochem, Germany).
FQ treated cells were lysed using caspase lysis buffer
(50 mM HEPES, pH 7.4; 100 mM Nacl; 0.1 % CHAPS;
1 mM DTT, 0.1 mM EDTA) supplemented with protease
inhibitor cocktail. 100 μg of total protein was incubated
with colorimetric caspase-3 substrate Ac-DEVD-pNA/
caspase-8 substrate Ac-IETD-pNA/caspase-9 substrate
Ac-LEHD-pNA in an assay buffer (50 mM HEPES,
pH 7.4; 100 mM Nacl; 0.1 % CHAPS; 10 mM DTT;
0.1 mM EDTA; 10 % Glycerol), at 37 °C for 3 h in dark.
Caspase activity assay is based on the ability of active en-
zyme to cleave the chromophore from the enzyme sub-
strates Ac-DEVD-pNA, Ac-IETD-pNA, Ac-LEHD-pNA
respectively. pNA released upon caspase cleavage pro-
duces a yellow color, which is measured by spectropho-
tometer at 405 nM. The amount of yellow color produced
is proportional to the amount of caspase activity present
in the sample. One unit is defined as the amount of en-
zyme that will cleave 1picomole of the substrate per mi-
nute at 37 °C and pH 7.4. Results are presented as the fold
change of the activity, in comparison with the untreated
control [22].
Mitochondrial membrane potential (Δψm)
The mitochondrial membrane potential was measured
with DiOC6 (3, 3′-dihexyloxacarbocyanine iodide; Sigma),
a fluorochrome that is incorporated into the cells depend-
ing upon the Δψm. Loss of DiOC6 fluorescence indicates
reduction in the mitochondrial inner transmembrane
potential, which was monitored using flow cytometer as
described before. In brief, FQ treated MIA PaCa-2 and
Panc-1 cells were stained with DiOC6 at a final concentra-
tion of 40 nM for 30 min at 37 °C in dark. Cells were
washed, and the fluorescence intensity was analysed by a
flow cytometer (Guava Technologies). A minimum of 5000
events were counted.Preparation of cell lysates and immunoblot analysis
Cell pellets obtained 48 h post treatment with FQ (0–
400 μg/ml) were lysed with cell lytic buffer containing
protease/phosphatase inhibitor cocktail purchased from
Sigma (St. Louis, Missouri, USA). Protein concentration
was determined using BCA (Sigma, St. Louis, Missouri,
USA) protein estimation kit. Equal amount of sample lys-
ate (90 μg for p21, p27 and 50 μg for rest of the proteins)
were separated by SDS-PAGE and transferred to PVDF
membrane. The membrane was blocked with 5 % skim
milk (3 % BSA in case of phospho form of protein) in
TBST and probed with primary antibody overnight fol-
lowed by incubation with appropriate secondary antibody
(ALP or HRP linked). After washing, blots were developed
using enzyme based chemiluminescence assays (alkaline
phosphatase) by BCIP-NBT (Sigma, Missouri, USA) or
enhanced chemiluminescence ECL western blot detection
system (Pierce, Illinois, USA). Measurement of signal in-
tensity of protein expression on PVDF membrane was
done using alphaimager 3400 (Alpha Innotech Corpor-
ation, San Leandro, California, USA) and normalized
using GAPDH as loading control. All data were expressed
as fold change. All the experiments were repeated three
times; representative results are presented [23].
Statistical analysis
Results are given as mean of three independent experi-
ments ± SEM. Statistical analysis was performed with stu-
dent’s two tailed t-test using SPSS (windows version 7.5);
values of p ≤ 0.05 were considered statistically significant.
Results
Fluoroquinolones inhibits proliferation of human
pancreatic cancer cells
To evaluate the effect of MFX and CFX on the prolifera-
tion of human pancreatic cancer cells MTT assay was
performed. As shown in Fig. 1, both the FQ inhibited
proliferation of MIA PaCa-2 and Panc-1 cells in a dose
(0–400 μg/ml) and time (0–48 h) dependent manner.
CFX was found to be more effective than MFX in sup-
pressing cellular proliferation at higher doses (100, 200,
400 μg/ml, p < 0.01). Since these doses were in accord-
ance with several previous reports [14, 15, 24–27] fur-
ther experiments were carried out at these doses.
Fluoroquinolones induce S-phase arrest and apoptosis in
pancreatic carcinoma cells
Next, to investigate whether FQ-induced cell death was
due to apoptosis, annexin assay was performed. As shown
in Table 1, CFX treatment led to statistical significant in-
crease in apoptosis at 200 μg/ml (p = 0.009) and 400 μg/
ml (p < 0.01) whereas MFX treatment led to increase in
percentage of apoptosis only at 400 μg/ml (p < 0.006) in
both the cell lines and at 24 h and 48 h respectively. We
Fig. 1 Antiproliferative effects of MFX and CFX on cultured pancreatic cancer cells. Dose and time dependent response of MFX and CFX on MIA
PaCa-2 (i), and Panc-1 (ii) cells, as assessed by MTT assay. Cells were seeded in 96 well plates (1 × 104 cells/well) which were allowed to adhere
overnight and were subsequently treated with increasing concentration of MFX and CFX for 24 h (a) and 48 h (b). Vertical axis represents %
proliferation rate whereas Horizontal axis represents increasing concentration of MFX and CFX in μg/ml. Data are mean ± SEM three independent
experiments performed in triplicate. *p < 0.01, #p < 0.05 versus control
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and MFX (100 and 200 μg/ml) in both the cell lines. Re-
sults of annexin-V were also validated using curcumin as
a positive control (data not shown).
As induction of apoptosis is often preceded by changes in
cell cycle kinetics, we next investigated the cell cycle
changes in presence of CFX/MFX in both the cell lines. In
congruence to our annexin results we found significant in-
crease in SubG1 peak either with MFX (400 μg/ml) or
CFX (200 and 400 μg/ml) treatment in both the cell lines
(Table 2 and 3). Interestingly in both the cell lines we ob-
served S-phase arrest at the lower doses of MFX and CFX
(100, 200 μg/ml) at 24 h and 48 h respectively.Table 1 Results representing the annexin assay after treatment of p
MIA Pa Ca-2 24 h 48 h
0 μg/ml 5 ± 2 % 1.6 ± 0.5 %
MFX 100 μg/ml 4.3 ± 0.64 % 4.4 ± 0.85 %
MFX 200 μg/ml 4.9 ± 0.6 % 5.9 ± 0.4 %
MFX 400 μg/ml 12.8 ± 1.2 % 23.4 ± 2 %
CFX 100 μg/ml 7.5 ± 0.3 % 7.9 ± 2.45 %
CFX 200 μg/ml 13.8 ± 0.6 % 22.5 ± 2 %
CFX 400 μg/ml 18.2 ± 0.2 % 40.6 ± 2.2 %
Values represent the percentage of apoptosisFluoroquinolones activates intrinsic and extrinsic
pathways of apoptosis
Caspases are important players in the apoptotic pathway
[28]. To address the involvement of caspases in FQ-
induced apoptosis, activity of caspase-3, −8 and −9 were
examined by colorimetric assay. As shown in Fig. 2a, sig-
nificant increase in the activity of caspase-8 (p = 0.003),
caspase-9 (p = 0.003), caspase-3 (p = 0.006) were ob-
served in both the cell lines following MFX (400 μg/ml)
and CFX (200 and 400 μg/ml) treatment for 48 h.
Several reports have demonstrated that caspase-8, and
its substrate BID (a pro-apoptotic Bcl-2 protein contain-
ing only the BH3 domain), are frequently activated inancreatic cancer cells with MFX/CFX
Panc-1 24 h 48 h
0 μg/ml 5.2 ± 0.58 % 4.2 ± 2.7 %
MFX 100 μg/ml 2.1 ± 2.7 % 4.6 ± 3.5 %
MFX 200 μg/ml 3.3 ± 1.59 % 7.9 ± 1.2 %
MFX 400 μg/ml 13 ± 1.15 % 16.9 ± 1.99 %
CFX 100 μg/ml 9.2 ± 1.8 % 9.8 ± 1.5 %
CFX 200 μg/ml 19 ± 3.4 % 14.6 ± 0.78 %
CFX 400 μg/ml 20.5 ± 1.8 % 21.6 ± 1.4 %
Table 2 Results representing the Cell cycle analysis of MFX and CFX treated MIA PaCa-2 cells
24 h Sub G1 G1 S G2 48 h Sub G1 G1 S G2
MIA PaCa-2 MIA PaCa-2
0 μg/ml 5 ± 0.5 53.8 ± 3.2 7.5 ± 1 33.7 ± 2.1 0 μg/ml 2.6 ± 0.5 67.1 ± 3 6.3 ± 1.2 24 ± 1.5
MFX 100 μg/ml 5.7 ± 0.35 48.2 ± 2.1 10.4 ± 1.1 35.7 ± 3.1 MFX 100 μg/ml 2.1 ± 1.1 63.7 ± 2.5 10.6 ± 0.9 23.6 ± 1
MFX 200 μg/ml 6.2 ± 0.4 60.6 ± 4 11 ± 1.2 22.2 ± 2.3 MFX 200 μg/ml 3.5 ± 2 54.3 ± 2 18.1 ± 0.8 24.1 ± 0.5
MFX 400 μg/ml 28 ± 1.5 49.1 ± 2.6 7.1 ± 1.5 15.8 ± 1.8 MFX 400 μg/ml 37.6 ± 2.1 40 ± 3.4 11 ± 1.2 11.4 ± 1.8
CFX 100 μg/ml 4.5 ± 0.6 63 ± 1.5 8.9 ± 2 23.6 ± 1.8 CFX 100 μg/ml 5.5 ± 1.7 51.5 ± 1.5 14.3 ± 0.6 28.7 ± 3
CFX 200 μg/ml 18.5 ± 2 55.2 ± 2.1 9.1 ± 1.3 17.2 ± 2.3 CFX 200 μg/ml 28.4 ± 1.9 52.8 ± 2 14 ± 1.1 4.8 ± 4.5
CFX 400 μg/ml 30.1 ± 2 48.1 ± 3 7.3 ± 2 14.5 ± 2.7 CFX 400 μg/ml 59.9 ± 1.1 32.2 ± 3.9 4.4 ± 2 3.5 ± 3.2
Values represent the percent of population in each phase. Values with significant changes have been highlighted with bold format
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independent manner. Once cleaved and activated it trans-
locates to the mitochondria and leads to mitochondrial
dysfunction and activation of caspase-9, which then trans-
duces apoptotic signals further [29]. To investigate the
possible involvement of Bid in FQ-induced cell death we
next checked the levels of uncleaved Bid in presence and
absence of both the FQs for 48 h. As expected, MFX (p <
0.008) and CFX (p < 0.01) treatment caused significant de-
crease in the levels of uncleaved BID in both the cell lines
in a dose dependent manner (Fig. 2b).
Literature reveals that a number of cellular proteins,
such as PARP, are cleaved following the activation of
caspases and capase-3 activation has been shown to be
required for DNA fragmentation [30]. Hence, we next
checked the cleavage of PARP by western blot analysis
and DNA fragmentation by agarose gel electrophoresis
48 h post CFX/MFX treatment. As shown in Fig. 2b, a
statistically significant increase in cleaved PARP was
seen in both the cell lines (p < 0.01). Furthermore, as ex-
pected, characteristic “ladder” pattern of apoptosis was
also observed in both the cell lines treated with either
MFX (400 μg/ml) or CFX (200-400 μg/ml) Fig. 2c.
Taken together our results indicate that a crosstalk ex-
ists between extrinsic and intrinsic pathway during MFX
and CFX induced apoptosis via Bid.Table 3 Results representing the Cell cycle analysis of MFX and CFX
24 h Sub G1 G1 S G2
Panc-1
0 μg/ml 4.8 ± 1.5 61.6 ± 0.5 7.8 ± 0.7 25.8 ± 0.9
MFX 100 μg/ml 4.4 ± 1 59.7 ± 2 9.7 ± 1 26.2 ± 2
MFX 200 μg/ml 5.6 ± 1.2 60.2 ± 1.2 11.6 ± 1.3 22.6 ± 1.4
MFX 400 μg/ml 10.4 ± 1 % 57.9 ± 2.5 7.1 ± 0.6 24.6 ± 1.5
CFX 100 μg/ml 5.1 ± 0.8 61 ± 1.3 8.4 ± 1 25.5 ± 0.5
CFX 200 μg/ml 24 ± 1.2 51 ± 2.1 9 ± 0.5 16 ± 1.6
CFX 400 μg/ml 32 ± 1.5 48.2 ± 3.2 7.3 ± 1 12.5 ± 2
Values represent the percent of population in each phase. Values with significant chFluoroquinolones induced apoptosis is caspase-8
dependent
In order to confirm the role of caspase-8 in FQ induced
apoptosis we first checked caspase-8 activity in a time
dependent manner. As shown in Fig. 3a, MFX and CFX
treatment led to significant increase in the caspase-8 activ-
ity from 6 h till 18 h (p < 0.01) in both the cell lines. Our
experimental findings (Fig. 3b and c) further reveal that
pre-treatment with caspase-8 inhibitor not only inhibited
activation of caspase-8 but also inhibited caspase-9 and
caspase-3 and simultaneously also rescued both the cell
lines from FQ-induced apoptosis.
In order to strengthen the involvement of caspases in
FQ induced apoptosis, we next checked the levels of
PARP, cleaved caspase-8, −9, and −3 in presence or ab-
sence of zVAD-fmk along with MFX/CFX. As shown in
Additional file 1: Figure S1, pre-treatment with zVAD-
fmk inhibited activation of cleaved caspase-8, −9, −3 and
PARP induced by MFX and CFX in both the cell lines.
Taken together our results suggest that FQs induces
apoptosis in a caspase-dependent manner.
Fluoroquinolones disrupts mitochondrial membrane
potential (Δψm)
A variety of key events during apoptosis involve the
mitochondria. Hence, to confirm the mitochondrialtreated Panc-1 cells
48 h Sub G1 G1 S G2
Panc-1
0 μg/ml 4.1 ± 0.8 66.2 ± 1 7.3 ± 0.5 22.4 ± 1.5
MFX 100 μg/ml 4 ± 0.5 56.7 ± 2.4 10.8 ± 1.5 28.5 ± 1
MFX 200 μg/ml 4.1 ± 1 50.3 ± 3.1 20.6 ± 2 24.6 ± 0.8
MFX 400 μg/ml 20.5 ± 2.5 52.8 ± 1.9 12.4 ± 1 14.3 ± 2.2
CFX 100 μg/ml 4.2 ± 1.1 53.6 ± 1.2 13.4 ± 1.5 28.8 ± 1.7
CFX 200 μg/ml 17.7 ± 2 50.2 ± 2.4 10.6 ± 1.1 21.5 ± 0.9
CFX 400 μg/ml 54.4 ± 1.5 28.9 ± 3.3 8.1 ± 0.8 8.6 ± 2.6
anges have been highlighted with bold format
Fig. 2 Effects of MFX and CFX on biochemical events associated with apoptosis. a As described in material and method, caspase-8, 9, 3 activities
were measured in MIA PaCa-2 (i), and Panc-1 cells (ii), in presence and absence of MFX/CFX for 48 h. The enzyme activity was measured by
extent of cleavage of the caspase substrates Ac-IETD-pNA, Ac-LEHD-pNA and Ac-DEVD-pNA respectively. Bar graph represents the mean ± SEM of
the fold increase in enzyme activity versus untreated control of three independent experiments performed in duplicates. Here vertical axis
represents fold change in caspase activity. *p < 0.015, #p < 0.05 b Western blot analysis of Bid activation and PARP cleavage in MIA PaCa-2 (i), and
Panc-1 cells (ii), treated with MFX/CFX in a dose dependent manner for 48 h. GAPDH was used as loading control. Data are representative of
typical experiment repeated three times with similar results. Bar Graph represents the mean ± SEM. here vertical axis represents fold change and
horizontal axis represents concentration in μg/ml. *p < 0.01 versus control. c DNA was isolated from MFX/CFX treated MIA PaCa-2 (i), and Panc-1
cells (ii) for 48 h, as described in material and method section, and was resolved onto 1.8 % agarose gel to detect DNA fragmentation, the
characteristic feature of cells undergoing apoptosis. Pictures are representative of three independent experiments. (1) represents standard DNA
marker, (2) DNA from untreated cells, (3) cells treated with 100 μg/ml of MFX, (4) cells treated with 200 μg/ml of MFX, (5) cells treated with
400 μg/ml of MFX, (6) cells treated with 100 μg/ml of CFX, (7) cells treated with 200 μg/ml of CFX, (8) cells treated with 400 μg/ml of CFX
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death, we checked mitochondrial membrane integrity
using the fluorescent probe DiOC6. The decrease in the
green fluorescence is a marker of mitochondrial mem-
brane potential dissipation and is measured as percent-
age of cells shifting towards the left. As shown in Fig. 4,
while MFX treatment at 400 μg/ml showed a marked
shift towards the left as compared to vehicle treated cells
in both the cell lines, we did not find similar shift when
cells were treated with 100, 200 μg/ml respectively. Simi-
lar to the above results, both the cell lines treated withCFX at 200 μg/ml and 400 μg/ml showed significant
shift towards left.
Taken together, all these results indicate that MFX and
CFX induce significant disruption of mitochondrial mem-
brane potential in both the cell lines. mCCCP was used as
positive control for DiOC6 experiments.
Fluoroquinolones modulates expression of apoptotic and
survival pathway proteins
In order to better understand the molecular basis of FQ-
induced apoptosis, the expression of several apoptotic
Fig. 3 MFX and CFX induced apoptosis is caspase-8 dependent in both the cell lines. a MFX and CFX induced Caspase-8 activity in a time dependent
manner in MIA Paca-2 (i), and Panc-1 cells (ii). Here vertical axis represents fold change in caspase activity and horizontal axis represents time in hours.
*p < 0.015, #p < 0.05 b Caspase-8, 9, 3 activity under the effect of MFX and CFX in presence or absence of caspase-8 inhibitor in MIA PaCa-2 (i), and
Panc-1 (ii) cells. *p < 0.015, #p < 0.05 versus MFX/CFX. c Abolishment of apoptosis in MIA PaCa-2 (i), and Panc-1 (ii), cells in presence of caspase-8
inhibitor as assessed by annexin-V assay. Cell death is represented in form of bar graph where vertical axis represents % apoptotic cells and horizontal
axis represents presence or absence of caspase-8 inhibitor (μM) along with MFX and CFX concentration in μg/ml. Bar graph represents mean ± SEM
from three independent experiments. *p < 0.015, #p < 0.05 versus MFX/CFX
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blotting. As shown in Fig. 5, MFX and CFX treatment
(400 μg/ml) led to statistically significant decrease in Bax
(p < 0.01) and Bcl-xL (p < 0.018) proteins in both cell lines
in a dose dependent manner. Previous studies, including
our lab have shown that Bax and Bak are functionally re-
dundant molecules and can substitute each other [31, 32].
Since in our study we found decrease in Bax, we also
checked the levels of Bak after CFX and MFX treatment
where we observed statistically significant increase in the
levels of Bak (p < 0.012) in both the cell lines.
Literature reveals that tumor suppressor protein p53
not only act as a master regulator of cell cycle arrest andapoptosis in various stress stimuli but also act as tran-
scription factor both for Bax and Bak [33]. Hence we
also checked the levels of p53 in both the cell lines
under the effect of FQ in a dose dependent manner. We
found statistically significant decrease in the levels of
p53 at 400 μg/ml of MFX (p < 0.001)/CFX (p < 0.006)
treatment in both the cell lines (Fig. 5). To rule out the
involvement of p53 in FQ-induced apoptosis we simul-
taneously performed annexin assay in HCT116 (human
colon cancer cell line) wild type p53+/+ and deficient
p53−/− cell lines in the presence of CFX/MFX. We
treated both the cell lines with MFX and CFX in a dose
dependent manner for 24 h and found insignificant
Fig. 4 MFX and CFX perturb mitochondrial membrane potential. Mitochondrial membrane potential disruption was estimated using DiOC6.
20 min prior to harvesting, cells were incubated with 40 nM DiOC6 and after incubation MIA PaCa-2 and Panc-1 cells were harvested, and the
change in fluorescence was measured by flowcytometry. The X-axis represents green fluorescence, and the Y-axis represents the count scale. The
illustrated histograms are representative of the three independent experiments with similar results. Results were also validated using mCCCp as a
positive control in both the cell lines
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HCT116 cell lines. Simultaneously we also checked the
expression of p53 protein and found that both MFX and
CFX decreased the levels of p53 similar to that in pan-
creatic cancer cell lines (Additional file 2: Figure S2).
Taken together our findings suggest that FQs induce
apoptosis in a p53 independent manner.
In addition to all these we also observed that MFX
and CFX down regulated the levels of proteins of the
survival pathways (c-Myc and AKT-ser 473) in a dose
dependent manner in both the cell lines. Although we
did not find any significant change in the levels of total
AKT after MFX treatment, but we observed CFX treat-
ment down-regulated the levels of total AKT in a dose
dependent manner in both the cell lines. These results
suggest that FQs induce apoptosis by modulating apop-
tosis and cell survival pathway related proteins.
Fluoroquinolones decreases the levels of S-Phase
regulatory CDKs and cyclins in both the cell lines
To identify the molecular mechanisms that govern the
FQ-induced S-phase arrest, we next assessed the effect ofFQs on the expression of cell cycle regulators of S-phase
progression [34]. We also checked the levels of Cip/Kip
family p21(Cip1) and p27(Kip1), which can inhibit cyclin
E- and cyclin A-CDK activities. We found that treatment
with MFX and CFX had a marked dose-dependent inhibi-
tory effect on the protein expression of cyclin-A, cyclin-E,
CDK2, p21 and p27 (Fig. 6) respectively. Although MFX
and CFX treatment (200 and 400 μg/ml) resulted in sig-
nificant decrease in the G2 phase population, they did not
cause significant change in the levels of G2-phase pro-
teins, i.e. CDC25c, cyclin-B1, pCDC2 (Additional file 3:
Figure S3). Our findings further strengthen that FQ induce
S-phase arrest by modulating the expression of S-phase
cell cycle regulatory proteins in both the cell lines.
Fluoroquinolones antiproliferative effects are ERK 1/2
dependent
Literature reveals that three subfamilies of MAPKs: ERK1/
2, JNK1/2, p38-MAPKs proteins cross-talks with other
regulatory proteins to cause cell cycle arrest and apoptosis
[35]. Hence, we next investigated the effect of both the
FQs on MAPK signalling pathway proteins. As shown in
Fig. 5 Effect of MFX and CFX on apoptotic and survival pathway proteins. Western blot analysis of apoptotic and survival pathway protein in MIA
PaCa-2 (a), and panc-1 cells (b), treated with MFX and CFX in a dose dependent manner. GAPDH was used as loading control. The protein bands
were quantified and normalized to GAPDH intensities. Data are representative of typical experiment repeated three times with similar results. Bar
Graph represents the mean ± SEM of the fold change from three independent experiments. *p < 0.01, #p < 0.05 versus control
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creased the expression of pERK1/2 in a dose dependent
manner in both the cell lines without affecting the levels
of total ERK. Also, there were insignificant changes in the
levels of p-JNK, JNK, p-P38, p38 after MFX treatment in
both the cell line. However CFX treatment decreased the
expression of total-p38 protein.
To confirm the role of ERK1/2 in FQ-induced apoptosis,
we next did annexin assay in presence or absence of
U0126. As shown in Fig. 8a, cells treated with U0126 for
1 h prior to addition of MFX/CFX (400 μg/ml) for 48 h,
showed a significant reduction of percentage of apoptotic
cells as compared to cells treated with MFX/CFX alone
(p < 0.01). To check the role of p38 in CFX induced apop-
tosis, we did annexin assay in presence or absence of
SB203580 (10 μM) along with CFX (400 μg/ml) for 48 h.
Inhibition of p38 by SB203580 either in presence or
absence of CFX did not showed significant change inapoptotic population, which confirms that FQ induced
apoptosis is p38 independent (Additional file 4: Figure S4).
Fluoroquinolones augments apoptotic effects of Cisplatin
in pancreatic cancer cells via ERK activation
Cisplatin is very well known broad spectrum anticancer
drug, which has been used in combination with other
chemotherapeutic agents in advanced stages of pancre-
atic cancer [36]. Antiproliferative and apoptotic effects
of Cisplatin have been attributed to activation of ERK in
various cell lines [37]. Since, we also found that FQ used
in our study show ERK dependent antiproliferative effect,
we herein investigated if both the FQs could augment the
apoptotic effects of cisplatin in pancreatic cancer cells. As
shown in Fig. 8bi, MFX (400 μg/ml, p < 0.008) and CFX
(400 μg/ml, p < 0.001) significantly enhances the apoptotic
potential of Cisplatin (20 μM) when given in combination
for 48 h. We also found the levels of pERK to be highly
Fig. 6 MFX and CFX effects S-phase associated regulatory proteins. Western blot analysis of S-phase regulatory Cyclins and CDKs in MIA PaCa-2
(a), and Panc-1 cells (b), treated with MFX and CFX in a dose dependent manner. GAPDH was used as loading control. The protein bands were
quantified and normalized to GAPDH intensities. Data are representative of typical experiment repeated three times with similar results. Bar Graph
represents the mean ± SEM of the fold change from three independent experiments. *p < 0.01, #p < 0.05 versus control
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cells treated alone with FQ or cisplatin without changes in
the levels of total-ERK (Fig. 8bii). Taken together, these re-
sults suggest that FQ augments the apoptotic effects of
cisplatin via ERK activation.
Discussion
Pancreatic carcinoma is the most aggressive forms of
malignancy, that warrants more treatment options owing
to its poor prognosis and single known drug therapy that
to facing the challenge of resistance [38]. The present
study characterizes the effects of MFX and CFX on cell
cycle arrest and apoptosis signalling in pancreatic cancer
cells. Herein we found that both the FQs caused cell
growth inhibition, S-phase cycle arrest and apoptosis in
pancreatic cancer cell lines MIA PaCa-2 and Panc-1 in a
dose and time-dependent manner at physiologically rele-
vant doses which are currently being used for the treat-
ment of antibacterial infections in humans [39].Literature reveals that coordinated action of Cyclin-A/
Cyclin-E with their respective kinase (CDK-2) cause S-
phase progression and inhibition of these cyclins and
CDKs leads to accumulation of cells in S-phase [40]. As
expected, in our current study too both the FQs signifi-
cantly downregulated the levels of Cyclin-A, Cyclin-E,
CDK2 without effecting the levels of G2-phase regulatory
proteins cyclin-B1, pCDC2 and CDC25c. Our previous
study [20] demonstrated that gatifloxacin caused S-phase
arrest via TGFβ1-smad-p21 pathway in MIA PaCa-2 cells
but herein we did not find any significant change in the
levels of TGFβ1 after CFX treatment in both the cell lines
and in fact significant decrease in the expression of
TGFβ1 was observed after MFX treatment in Mia PaCa-2
cells (data not shown). Our results rule out the involve-
ment of TGFβ1 in CFX and MFX induced S-phase arrest,
and apoptosis. Our current findings were also in contrast
to the study of Bourikas LA et al., where they demon-
strated that the anti-proliferative and immunoregulatory
Fig. 7 Effects of MFX and CFX on MAPK signalling pathway proteins Western blot analysis of MAPK pathway protein in MIA PaCa-2 (a), and panc-1 cells
(b), treated with MFX and CFX in a dose dependent manner. GAPDH was used as loading control. The protein bands were quantified and normalized to
GAPDH intensities. Data are representative of typical experiment repeated three times with similar results. Bar Graph represents the mean ± SEM of the
fold change from three independent experiments. *p < 0.01, #p < 0.05 versus control
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diated by TGFβ1 and it had no effect on Caco-2 a human
colonic epithelial cell line that lacks functional TGFβ1 re-
ceptors [25]. The difference in mechanistic action of CFX
in our study and their study could be attributed to the dif-
ference in origin of both the cell types. Increasing evi-
dences in the literature show that different molecular
pathways can be activated by diverse FQs in the same cell
line [41].
Various evidences suggest that apoptosis is character-
ized by certain hallmarks such as phosphatidyl serine ex-
posure to plasma membrane, activation of caspase −8, −9,
−3 and DNA fragmentation [42]. Our annexin, cell cycle
analysis, caspase activation, cleavage of poly(ADP-ribose)
polymerase (PARP) and DNA fragmentation assay clearly
demonstrates that both the FQs induces apoptosis in pan-
creatic cancer cell lines. We further observed CFX to be
more potent than MFX in inhibiting proliferation and in-
duction of apoptosis in both the cell lines. A decrease infull-length Bid, suggests a possible cross-talk between the
intrinsic and extrinsic apoptotic pathway during FQ in-
duced apoptosis in both the cell lines. Our study is in ac-
cordance to the reports by Aranha O et al., and Herold C
et al., where they observed that CFX activates all the three
caspases in colorectal carcinoma and bladder cancer cell
lines at similar doses [14, 24].
There is mounting evidence implicating that members
of the B-cell lymphoma-2 (BCL-2) family regulate the
mitochondrial pathway of apoptosis by controlling the
permeabilization of the outer mitochondrial membrane.
The pro- and anti-apoptotic members such as Bax, Bak
and Bcl-xL reside on outer mitochondrial membrane or
cytosol and oligomerize under stress to facilitate the re-
lease of factors from mitochondria to trigger apoptosis. In
the current study, MFX and CFX treatment resulted in
significant increase in the expression of Bak along with de-
crease in Bax/Bcl2 ratio contributing towards the involve-
ment of mitochondrial mediated intrinsic pathway in FQ
Fig. 8 a MFX and CFX causes ERK mediated apoptosis in pancreatic cancer cells. (i) Abolishment of apoptosis in MIA PaCa-2 cells as assessed by
annexin-V assay. Left panel represents the bar graph where vertical axis represents % apoptotic cells and horizontal axis represents MFX and CFX
concentration in μg/ml, and U0126 concentration in μM. Bar graph represents mean ± SEM from three independent experiments. *p < 0.01 versus
MFX/CFX alone. Right panel shows western blot for the knockdown efficiency of ERK1/2 inhibitor (U0126). (ii) Abolishment of apoptosis in Panc-1
cells as assessed by annexin-V assay. Left panel represents the bar graph where vertical axis represents % apoptotic cells and horizontal axis
represents MFX and CFX concentration in μg/ml, and U0126 concentration in μM. Bar graph represents mean ± SEM from three independent
experiments. *p < 0.01 versus MFX/CFX alone. Right panel shows western blot for the knockdown efficiency of ERK1/2 inhibitor (U0126). (1) represents
untreated control cells, (2) U0126 treated cells, (3) cells treated with 400 μg/ml of MFX alone, (4) U0126 treated cells with 400 μg/ml of MFX, (5) cells
treated with 400 μg/ml of CFX alone, (6) U0126 treated cells with 400 μg/ml of CFX. b MFX and CFX augment apoptotic effects of cisplatin via ERK
activation in pancreatic cancer cells. (i) Annexin-V assay of MIA PaCa-2 cells treated either alone with MFX and CFX (400 μg/ml) or in combination with
cisplatin(CDDP) 20 μM for 48 h. (ii) Western blot analysis for pERK expression in MIA PaCa-2 cells treated either with MFX, CFX & CDDP alone or in
combination for 48 h. Bar Graph represents the mean ± SEM of the fold change from three independent experiments. *p < 0.01, #p < 0.05 versus control
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vival pathways is a strategy normally used to induce apop-
tosis in cancer cells. In our study we too observed that
both the FQs not only downregulates anti-apoptotic pro-
teins, upregulates pro-apoptotic proteins but also downre-
gulates pro-survival proteins (c-Myc, AKT) in both the
cell lines. AKT (Serine/Threonine kinases) is known to be
involved in promoting cellular proliferation by regulating
cell cycle and apoptosis [43]. Literature reveals that acti-
vated AKT not only prevents apoptosis but also confers
resistance against chemotherapy and increasing evidencesreveal that AKT inhibition prior to chemotherapy in-
creases the efficacy of chemotherapeutic drugs [44].
Extracellular signal-related kinase (ERK) activation has
been majorly known to regulate cellular proliferation
and survival, but ERK1/2 pathway has also been known
to be associated with various other processes such as dif-
ferentiation, proliferation, transformation and apoptosis
[35, 45, 46]. Several investigators independently reported
activated ERK1/2 in induction of cell cycle arrest and
apoptosis by various cytotoxic agents such as Asiatic
acid, Pemetrexed, Phenethyl Isothiocyanate, Lauryl gallate,
Yadav et al. BMC Cancer  (2015) 15:581 Page 13 of 15Taxol [47–51]. Literature also reveals that various antican-
cer agents such as etoposide, adriamycin and cisplatin also
require prolonged activation of ERK1/2 as a prerequisite
molecule for apoptosis induction in variety of primary or
secondary immortalized and transformed cells [52]. Some
studies suggest that ERK1/2 showed its apoptotic effects
by targeting various downstream targets such as cMyc,
Elk1 and p53 [53] whereas others suggest ERK1/2 medi-
ated apoptosis is a result of balance between intensity and
duration of pro- versus anti-apoptotic proteins [54]. Simi-
lar to our findings Cagnol et al., in their study reported
that prolonged activation of ERK1/2 induces FADD inde-
pendent caspase-8 activation and cell death [55]. In our
study we found that activation of ERK1/2 is involved in
FQ mediated apoptosis as suggested by the use of U0126
(a highly selective inhibitor of both MEK1 and MEK2, a
type of MAPK/ERK kinase). Our results are in accordance
to one of the recent report by Jemel-Oualha et al., whereFig. 9 Proposed mechanism of action of MFX and CFX induced S-phase arre
levels of Cyclin-A, Cyclin-E, CDK2, p21 and p27 in both the cell lines. Both FQs
and ERK1/2 which then disrupts mitochondrial membrane potential via activa
antiapoptotic protein Bcl-xL, which finally promotes activation of caspase-9,3
survival pathway by downregulating the levels of pAKT and cMYCthey have shown CFX to induce ERK mediated apoptosis
in colon cancer cells [56]. In contrast to our study there is
a report by Zheng et al., where ERK activation has been
associated with gemcitabine resistance in pancreatic can-
cer cells [57]. However, the mechanism by which ERK1/2
activation mediates FQ-induced apoptosis varies depend-
ing on the context and needs further investigation.
Furthermore, in general tumour suppressor genes such
as p53, p27 and p21 are up regulated during apoptosis but
in our study they are down regulated. One should remem-
ber that tumour suppressor functions of genes/proteins
are context-dependent and may be influenced by numer-
ous factors, including cell type, the type of stress signal,
microenvironment and their expression levels at the time
of exposure to stress. Similar to our findings Tang et al., in
their study reported that prolonged activation of ERK
causes cell cycle arrest and apoptosis after DNA damage
independent of p53 status [58]. How and why thesest and apoptosis. MFX and CFX causes S-phase arrest by decreasing the
also leads to activation of extrinsic pathway of apoptosis via caspase-8
tion of Bid and proapoptotic Bak, as well as downregulates Bax and
and leads to apoptosis. Furthermore MFX and CFX also suppresses cell
Yadav et al. BMC Cancer  (2015) 15:581 Page 14 of 15tumour suppressor proteins are down regulated during
FQ-mediated apoptosis remains an active area of investi-
gation which is currently being investigated.
According to above results we herein propose a model
for mode of action of both the FQs in pancreatic cancer
cells as shown in Fig. 9.
Conclusion
We demonstrated that induction of apoptotic cell death
and S-phase arrest contributes to the anti proliferative ef-
fect of MFX and CFX in pancreatic cancer cell lines, MIA
PaCa-2 and Panc-1 cells. CFX was found to be more potent
in inducing apoptosis than MFX in both the cell lines. In
addition we showed that MFX and CFX not only cause S-
phase arrest and apoptosis individually, but also augments
Cisplatin induced apoptosis in human pancreatic cancer
cells in ERK1/2 dependent manner. We believe that our
data would contribute to the development of MFX and
CFX as potential neo-adjuvant chemotherapeutic agents for
the treatment of pancreatic cancer. However, one major
limitation of the study is that all data are derived from
in vitro systems and in vivo validation is extremely import-
ant for these agents to become as therapeutics for cancer.
Additional files
Additional file 1: Figure S1. MFX and CFX induced apoptosis is
caspase-dependent in both the cell lines. Western blot of cleaved
caspase-8, 9, 3, and PARP under the effect of MFX (400 μg/ml) and CFX
(400 μg/ml) in presence or absence of zVAD-fmk (Pan caspase inhibitor,
20 μM) (JPEG 377 kb)
Additional file 2: Figure S2. MFX and CFX induced apoptosis is
independent of p53 status. (i) Annexin-V assay ofHCT116 p53+/+ and
p53 −/− treated with MFX and CFX (400 μg/ml) for 24 h. Bar graph
represents mean ± SEM from three independent experiments, where vertical
axis represents % apoptotic cells and horizontal axis represents MFX and
CFX (400 μg/ml)concentration. (ii) Western blot analysis for p53 expression
in HCT116 p53+/+ and p53 −/− cell lines treated with MFX and CFX in a
dose dependent manner (0–400 μg/ml) for 24 h. (JPEG 335 kb)
Additional file 3: Figure S3. MFX and CFX do not affect G2-phase
associated regulatory proteins. Western blot analysis of G2-phase
regulatory Cyclins and CDKs in MIA PaCa-2 and Panc-1 cells treated
with MFX and CFX in a dose dependent manner. GAPDH was used
as loading control. (JPEG 397 kb)
Additional file 4: Figure S4. CFX induced apoptosis is independent of
p38 in pancreatic cancer cells. (i) Annexin V-PE assay in MIA PaCa-2 cells
treated with CFX in presence and absence of SB203580 (10 μM). Results are
represented in the form of bar graph where vertical axis represents %
apoptotic cells and horizontal axis represents presence or absence of CFX
and SB203580. Bar graph represents mean ± SEM from three independent
experiments. (ii) Western blot analysis for the knockdown efficiency of p38
inhibitor (SB203580) in presence and absence of CFX. (JPEG 278 kb)
Abbreviations
FQ: Fluoroquinolone; MFX: Moxifloxacin; CFX: Ciprofloxacin; CDDP: Cisplatin;
ERK: Extracellular-signal-regulated kinase; JNK: c-JUN N-terminal kinase;
CDK: Cyclin dependent kinase; MAPK: Mitogen-activated protein kinase;
PARP: Poly(ADP-ribose) polymerase; U0126: ERK inhibitor;
EDTA: Ethylenediaminetetraacetic acid; TGFβ1: Transforming growth factor- β1;
SB203580: p38 inhibitor; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
VY, NS Conceived and designed the study. VY performed FACS based
experiments, caspase activity assay, immunoblot assay. PV carried out DNA
fragmentation assay and participated in immunoblot assay. JY, NS
contributed material and reagents. VY, JY, SS, NS critically analyzed the data
and made interpretation. VY, NS drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgement
This work was supported by grants BSC0123 from the council of scientific
and industrial research (CSIR), India. VY and PV were supported with
fellowship from CSIR.
Author details
1CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road,
Delhi, India. 2Department of Medical Elementology and Toxicology, Jamia
Hamdard (Hamdard University), Hamdard Nagar, New Delhi, India.
Received: 8 February 2015 Accepted: 15 July 2015
References
1. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg.
1995;221:133–48.
2. Kamphues C, Bova R, Schricke D, Hippler-Benscheidt M, Klauschen F,
Stenzinger A, et al. Postoperative complications deteriorate long-term
outcome in pancreatic cancer patients. Ann Surg Oncol. 2012;19:856–63.
3. Ozaki H, Kinoshita T, Kosuge T, Shimada K, Yamamoto J, Tokuuye K, et al.
Long-term survival after multimodality treatment for resectable pancreatic
cancer. Int J Pancreatol. 2000;27:217–24.
4. Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL,
et al. Phase II study of gemcitabine and erlotinib as adjuvant therapy for
patients with resected pancreatic cancer. Ann Surg Oncol. 2011;18:1122–9.
5. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J,
et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer:
long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107:dju413.
6. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, et al. Overcoming drug
resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15:817–28.
7. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol.
1999;2:504–8.
8. Shen LL, Baranowski J, Pernet AG. Mechanism of inhibition of DNA gyrase
by quinolone antibacterials: specificity and cooperativity of drug binding to
DNA. Biochemistry. 1989;28:3879–85.
9. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of
cytokines by human monocytes stimulated with lipopolysaccharide. Clin
Microbiol Infect. 2002;8:26–30.
10. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection.
2005;33 Suppl 2:55–70.
11. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis.
Cochrane Database Syst Rev. 2008;1:CD004795.
12. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I. Moxifloxacin
enhances antiproliferative and apoptotic effects of etoposide but inhibits its
proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer. 2006;95:1038–46.
13. Gurbay A, Osman M, Favier A, Hincal F. Ciprofloxacin-Induced Cytotoxicity
and Apoptosis in HeLa Cells. Toxicol Mech Methods. 2005;15:339–42.
14. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D.
Ciprofloxacin induces apoptosis and inhibits proliferation of human
colorectal carcinoma cells. Br J Cancer. 2002;86:443–8.
15. Mondal ER, Das SK, Mukherjee P. Comparative evaluation of
antiproliferative activity and induction of apoptosis by some
fluoroquinolones with a human non-small cell lung cancer cell line in
culture. Asian Pac J Cancer Prev. 2004;5:196–204.
16. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I. Quinolones as
enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I
effects. Biochem Pharmacol. 2008;75:1272–81.
17. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I. Moxifloxacin enhances
etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects
in a human colon carcinoma cell line. Int J Oncol. 2010;37:463–71.
Yadav et al. BMC Cancer  (2015) 15:581 Page 15 of 1518. Reuveni D, Halperin D, Fabian I, Tsarfaty G, Askenasy N, Shalit I.
Moxifloxacin increases anti-tumor and anti-angiogenic activity of
irinotecan in human xenograft tumors. Biochem Pharmacol.
2010;79:1100–7.
19. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative
analysis of mutations in the p53 and k-ras genes in pancreatic cancer.
Int J Cancer. 1994;58:158–91.
20. Yadav V, Sultana S, Yadav J, Saini N. Gatifloxacin induces S and G2-phase cell
cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS One.
2012;7:e47796.
21. Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N. Apoptogenic effect of
7,8-diacetoxy-4-methylcoumarin and 7,8-diacetoxy-4-methylthiocoumarin
in human lung adenocarcinoma cell line: role of NF-kappaB, Akt, ROS
and MAP kinase pathway. Chem Biol Interact. 2009;179:363–74.
22. Singh R, Saini N. Downregulation of BCL2 by miRNAs augments drug-induced
apoptosis–a combined computational and experimental approach. J Cell Sci.
2012;125:1568–78.
23. Dubey R, Chhabra R, Saini N. Small interfering RNA against transcription
factor STAT6 leads to increased cholesterol synthesis in lung cancer cell
lines. PLoS One. 2011;6:e28509.
24. Aranha O, Wood Jr DP, Sarkar FH. Ciprofloxacin mediated cell growth
inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional
cell carcinoma of the bladder cell line. Clin Cancer Res. 2000;6:891–900.
25. Bourikas LA, Kolios G, Valatas V, Notas G, Drygiannakis I, Pelagiadis I,
et al. Ciprofloxacin decreases survival in HT-29 cells via the induction of
TGF-beta1 secretion and enhances the anti-proliferative effect of
5-fluorouracil. Br J Pharmacol. 2009;157:362–70.
26. Engeler DS, Scandella E, Ludewig B, Schmid HP. Ciprofloxacin and
epirubicin synergistically induce apoptosis in human urothelial cancer cell
lines. Urol Int. 2012;88:343–9.
27. Kloskowski T, Gurtowska N, Olkowska J, Nowak JM, Adamowicz J,
Tworkiewicz J, et al. Ciprofloxacin is a potential topoisomerase II inhibitor
for the treatment of NSCLC. Int J Oncol. 2012;41:1943–9.
28. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways
of caspase activation during apoptosis. Annu Rev Cell Dev Biol.
1999;15:269–90.
29. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the
cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41.
30. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A
caspase-activated DNase that degrades DNA during apoptosis, and its
inhibitor ICAD. Nature. 1998;391:43–50.
31. Adlakha YK, Saini N. MicroRNA-128 downregulates Bax and induces
apoptosis in human embryonic kidney cells. Cell Mol Life Sci.
2011;68:1415–28.
32. Wei MC, Zong WX, Cheng EH, Lindsten T, Ross AJ, Roth KA, et al.
Proapoptotic Bax and Bak: a requisite gateway to mitochondrial disfunction
and death. Science. 2001;292:727–30.
33. Oren M. Decision making by p53: Life death and Cancer. Cell Death Differ.
2003;10:431–42.
34. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, et al.
Cyclin-dependent kinases: a family portrait. Nat Cell Biol. 2009;11:1275–6.
35. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis
regulation. Oncogene. 2004;23:2838–49.
36. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger
HJ, et al. Gemcitabine and cisplatin in the treatment of advanced or
metastatic pancreatic cancer. Ann Oncol. 2000;11:1399–403.
37. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in
cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435–43.
38. Kim MP, Evans DB, Vu TM, Fleming JB. The recognition and surgical
management of heritable lesions of the pancreas. Surg Oncol Clin N Am.
2009;18:99–119.
39. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood Jr DP, Sarkar FH.
Suppression of human prostate cancer cell growth by ciprofloxacin is
associated with cell cycle arrest and apoptosis. Int J Oncol. 2003;22:787–94.
40. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins,
cyclin dependent kinases (CDKs), growth suppressor genes and
cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211–9.
41. Blau H, Klein K, Shalit I, Halperin D, Fabian I. Moxifloxacin but not
ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and
NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol
Lung Cell Mol Physiol. 2007;292:L343–52.42. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL:
apoptosis through mitochondrial-dependent and -independent pathways.
Oncogene. 2001;20:2122–33.
43. Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: a double-edged sword in cell
proliferation and genome stability. J Oncol. 2012;2012:951724.
44. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is
associated with chemosensitisation in the pancreatic cancer cell line
MIA-PaCa-2. Br J Cancer. 2003;89:391–7.
45. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell
Mol Life Sci. 1999;55:1230–54.
46. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell
proliferation in mammalian cells. Cell Res. 2002;12:9-18
47. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, et al.
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38)
and is independent of p53. Oncogene. 2001;20:147–55.
48. Calcabrini A, Garcia-Martinez JM, Gonzalez L, Tendero MJ, Ortuno MT,
Crateri P, et al. Inhibition of proliferation and induction of apoptosis in
human breast cancer cells by lauryl gallate. Carcinogenesis.
2006;27:1699–712.
49. Hsu YL, Kuo PL, Lin LT, Lin CC. Asiatic acid, a triterpene, induces apoptosis
and cell cycle arrest through activation of extracellular signal-regulated
kinase and p38 mitogen-activated protein kinase pathways in human breast
cancer cells. J Pharmacol Exp Ther. 2005;313:333–44.
50. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Sheu GT, et al. Sustained
activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed
leading to S-phase arrest and apoptosis in human non-small cell lung
cancer A549 cells. Eur J Pharmacol. 2011;663:17–26.
51. Xiao D, Lew KL, Zeng Y, Xiao H, Marynowski SW, Dhir R, et al. Phenethyl
isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is
mediated by reactive oxygen species-dependent disruption of the
mitochondrial membrane potential. Carcinogenesis. 2006;27:2223–34.
52. Cagnol S, Chambard JC. ERK and cell death: mechanism of ERK induced cell
death-apoptosis, autophagy and senescence. FEBS J. 2010;277:2–21.
53. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, et al.
ERK phosphorylation potentiates Elk-1-mediated ternary complex formation
and transactivation. EMBO J. 1995;14:951–62.
54. Kim GS, Hong JS, Kim SW, Koh JM, An CS, Cheng SL. Leptin induces
apoptosis via ERK/cPLA2/cytochrome pathway in human bone marrow
stromal cells. J Biol Chem. 2003;278:21920–9.
55. Cagnol S, Van Obberghen-Schilling E, Chambard JC. Prolonged activation of
ERK1,2 induces FADD-independent caspase 8 activation and cell death.
Apoptosis. 2006;11:337–46.
56. Jemel-Oualha I, Elloumi-Mseddi J, Beji A, Hakim B, Aifa S. Controversial effect
on Erk activation of some cytotoxic drugs in human LOVO colon cancer
cells. J Recept Signal Transduct Res. 2014;24:1–5.
57. Zheng C, Jiao X, Jiang Y, Sun S. ERK1/2 contributes to gemcitabine
resistance in pancreatic cancer cells. J Intl Med Res. 2013;41:300–6.
58. Tang D, Tang D, Wu D, Hirao A, Lahti JM, Liu L, et al. ERK activation
mediates cell cycle arrest and apoptosis after DNA damage independently
of p53. J Biol Chem. 2002;277:12710–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
